Recently

our understanding of the pathogenesis and molecular genetic characteristics of endometrial cancer has been improved along with the development of high-throughput sequencing technology. Precision medicine based on genetic characteristics has already transformed the care of endometrial cancer. However

there is no specific consensus in China on the methods and strategies of genetic screening for hereditary syndrome

molecular classification and other biomarkers testing in endometrial cancer. Based on the most recent advances in molecular classification and precision medicine in endometrial cancer

The Society of Gynecological Cancer of China Anti-Cancer Association

Chinese Society of Pathology of the Chinese Medical Association and National Pathology Quality Control Center have formulated “The Chinese Expert Consensus Recommendations on Molecular Testing in Endometrial Cancer”

in order to improve the understanding of molecular testing among gynecologic oncologists

pathologists

and other specialists

and further standardize the application of molecular testing in endometrial cancer in China.